Clinical Trial Update: An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

View source ↗

Summary

This document describes an Early Access Program Guideline to provide access to retifanlimab (INCMGA00012) with carboplatin and paclitaxel for squamous cell carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Anal Canal

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Incyte Corporation | Conditions: Squamous Cell Carcinoma of the Anal Canal | Status: AVAILABLE